WeVote
Log In

Bill

Bill

S 3017

Shifts $45 million appropriation for opioid related care and treatment provided at certain hospitals from Opioid Recovery and Remediation Fund to General Fund.

2026-2027 Regular Session Introduced by Bob Singer and 3 co-sponsors

New Jersey bill redirects $45 million from opioid-specific fund to general budget while maintaining current hospital treatment services.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
0
WeVote Research Nonpartisan
Bill Summary · S 3017

Legislative bill overview

S 3017 redirects $45 million in annual appropriations from New Jersey's dedicated Opioid Recovery and Remediation Fund to the General Fund, while maintaining opioid care and treatment services at specified hospitals. The shift essentially repurposes money previously earmarked specifically for opioid programs to cover broader state budget needs.

Why this is important

This reallocation affects how states finance their opioid crisis response. The General Fund supports all state operations, meaning this money could be used for any state priority. This move signals either confidence that opioid programs are sufficiently funded through other means, or budget pressure requiring reallocation of previously dedicated resources.

Potential points of contention

  • Fund depletion concerns: The Opioid Recovery and Remediation Fund was created specifically from opioid settlement revenues; redirecting it may signal the fund's depletion or reduced future revenue expectations
  • Program sustainability: While current hospital services are protected, removing dedicated funding could make future opioid treatment expansions or improvements more difficult
  • Equity in budget priorities: Critics may argue dedicated opioid funds should remain protected given the ongoing public health crisis; supporters may counter that general budget flexibility is needed

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.